Brief: Pharmacyte Biotech Successfully Completes 24-Month Stability Study Of Its Clinical Trial Product Candidate
22/03/2022 13:26
March 22 (Reuters) - PharmaCyte Biotech Inc PMCB.O :
* PHARMACYTE BIOTECH SUCCESSFULLY COMPLETES 24-MONTH
STABILITY
STUDY OF ITS CLINICAL TRIAL PRODUCT CANDIDATE
* PHARMACYTE BIOTECH INC - CYPCAPS HAS NOW DEMONSTRATED THAT
IT
HAS A SHELF LIFE OF AT LEAST 24 MONTHS WHEN STORED AT -80OC
Source text for Eikon: ID:nBwqRn6Ja
Further company coverage: PMCB.O
Recent news on Pharmacyte Biotech
See all newsBrief: Pharmacyte Biotech Inc - Increases Stake In Tnf Pharmaceuticals By $3 Million
Brief: PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Pharmacyte Biotech Announces Final Results Of Tender Offer